The CMTM5 (CKLF-like MARVEL transmembrane domain-containing protein 5) antibody is a tool used to detect and study the CMTM5 protein, a member of the chemokine-like factor (CKLF) and MARVEL domain-containing protein family. CMTM5 is encoded by the *CMTM5* gene located on human chromosome 14q11.2. This protein contains a MARVEL domain, implicated in membrane apposition and vesicle trafficking, and transmembrane regions critical for its localization to the plasma membrane and intracellular vesicles.
CMTM5 is recognized as a tumor suppressor, frequently downregulated in various cancers, including prostate, lung, and gastric cancers, due to promoter hypermethylation. It regulates key signaling pathways, such as EGFR and Wnt/β-catenin, and modulates cell proliferation, apoptosis, and metastasis. Research using CMTM5 antibodies has highlighted its role in inhibiting epithelial-mesenchymal transition (EMT) and maintaining cell adhesion by stabilizing E-cadherin expression.
Antibodies targeting CMTM5 are essential in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression patterns in normal and pathological tissues. These studies contribute to understanding CMTM5’s involvement in cancer progression, immune regulation, and potential therapeutic targeting. Additionally, CMTM5’s interaction with other molecules, such as PD-L1. suggests broader implications in immune evasion, linking it to immunotherapy research. Its dual role in tumor suppression and immune modulation makes CMTM5 a compelling biomarker and therapeutic candidate.